Nykode Therapeutics ASA banner
N

Nykode Therapeutics ASA
OSE:NYKD

Watchlist Manager
Nykode Therapeutics ASA
OSE:NYKD
Watchlist
Price: 3.816 NOK 5.07%
Market Cap: kr1.2B

Wall Street
Price Targets

NYKD Price Targets Summary
Nykode Therapeutics ASA

Wall Street analysts forecast NYKD stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NYKD is 2.244 NOK with a low forecast of 2.222 NOK and a high forecast of 2.31 NOK.

Lowest
Price Target
2.222 NOK
42% Downside
Average
Price Target
2.244 NOK
41% Downside
Highest
Price Target
2.31 NOK
39% Downside
Nykode Therapeutics ASA Competitors:
Price Targets
PTEN
Patterson-UTI Energy Inc
-12% Downside
AMSF
Amerisafe Inc
32% Upside
BRI
Britania PCL
7% Upside
QXO
SilverSun Technologies Inc
25% Upside
PRQR
ProQR Therapeutics NV
582% Upside

Revenue
Forecast

110% / Year
Past Growth
-46% / Year
Estimated Growth
Estimates Accuracy
N/A
Average
110% / Year
Past Growth
-46% / Year
Estimated Growth
Estimates Accuracy
N/A
Average

For the last 7 years the compound annual growth rate for Nykode Therapeutics ASA's revenue is 110%. The projected CAGR for the next 3 years is -46%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is NYKD's stock price target?
Price Target
2.244 NOK

According to Wall Street analysts, the average 1-year price target for NYKD is 2.244 NOK with a low forecast of 2.222 NOK and a high forecast of 2.31 NOK.

What is Nykode Therapeutics ASA's Revenue forecast?
Projected CAGR
-46%

For the last 7 years the compound annual growth rate for Nykode Therapeutics ASA's revenue is 110%. The projected CAGR for the next 3 years is -46%.

Back to Top